drugset / Trial / NCT04209530

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530

Phase 2 Terminated 7 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).

Timeline

Start
2019-11-20
Primary completion
2020-07-23
Completion
2020-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 1.68 mg

Indications